Emergent BioSolutions (EBS) Misses Q2 EPS by 137c; offers guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.46 +3.86%
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: -45.6%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($2.32), $1.37 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $254.7 million versus the consensus estimate of $190 million.
GUIDANCE
Emergent BioSolutions sees FY2024 revenue of $1.050 - $1.125 billion versus the consensus of $1.033 billion
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Starts Aequs Ltd (AEQUS:IN) at Reduce (3)
- BNP Paribas Exane Starts NHPC Ltd (NHPC:IN) at Underperform
- Five Below raises full-year outlook after strong second-quarter sales growth
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
